Ready-to-fill syringe systems made of glass or COP for sensitive biologics and special applications
Supply and license agreement with Injecto Group for long-term availability of silicone-oil-free plunger stoppers
Düsseldorf / Bünde, April 22, 2025 - Gerresheimer, innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, is now offering complete, silicone-oil- and PFAS-free syringe systems made of glass and cyclic olefin polymer (COP). Avoiding silicone-oil significantly reduces particle load and thus minimizes potential medical risks and side effects. Silicone-oil-free syringe systems are therefore particularly suitable for sensitive biologics and areas of application with particularly high requirements, such as ophthalmology. Gerresheimer has now extended its existing cooperation with the Injecto Group A/S and concluded a supply and license agreement with the Danish supplier. Gerresheimer has thus secured the long-term availability of Injecto's patented plunger stoppers. Gerresheimer customers benefit from complete ready-to-fill (RTF) syringe systems from a single source with validated functionality. With the silicone-oil- and PFAS-free syringe systems made of glass and COP, Gerresheimer is underlining its positioning as an innovative system and solution provider for the pharma and biotech industry
“Silicone-oil-free syringe systems are ideal for the administration of sensitive biologics and for ophthalmic applications,” explains Torben Helmer, CEO of Injecto Group A/S. “As part of the agreement, we are providing our patented plunger stoppers for a function-tested silicone-oil- and PFAS-free syringe system from Gerresheimer that meets the highest standards.”
“The new Gerresheimer RTF syringe systems made of glass and COP with Injecto plunger stoppers allow precise dosing and offer outstanding functionality – completely without silicone-oil or PFAS,” says Oliver Burgel, Global Executive Vice President Syringe Systems at Gerresheimer. “We are pleased that the supply and license agreement with Injecto enables us to guarantee the long-term availability of this innovative syringe configuration for our customers.”
Licensing of patented technology The agreement now concluded governs the continued supply of Injecto plunger stoppers for Gerresheimer's silicone-oil- and PFAS-free syringe systems, including conditional access to technology and know-how for the production. This enables Gerresheimer to ensure the long-term availability of the patented plunger stoppers for the silicone-oil-free syringe systems.
About Injecto Injecto is specialised in development, production and supply of patented plunger stoppers for pre-fillable syringes. Injecto’s environmentally friendly lubrigone plunger stoppers set new standards for glass or polymer-based prefilled syringes, enabling a completely silicone-oil-free and PFAS-free injection system. Injecto has a strong IPR portfolio, and a lean organisation based on networks, partnerships, and strategic alliances. Injecto’s ISO class 7 clean room production in Denmark is supplying customers with high-quality products that contributes to ensuring safe and effective drug delivery to patients. Injecto is a subsidiary of the Danish company, Injecto Group A/S, and hence a member of the company group with headquarters in Copenhagen, Denmark. http://injecto.eu
About Gerresheimer Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma 2024, the Group generated revenues of around EUR 2.4bn and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
